Special Issue

What's New: Natural and Synthetic Antibacterials and/or Agents with Multiple Activities?

Message from the Guest Editor

Despite the success of the discovery of ever new antimicrobials and advances in the techniques for their production, infectious diseases still remain the second leading cause of death worldwide. Self-medication and overuse of these drugs are important factors that contribute to antimicrobial resistance, leading to the constant need for research and development of new antibiotics. Today, an important goal is the discovery of new antibacterials endowed, as well, with other biological activities for high incidence diseases. For this reason, many efforts have been made in the study and biological evaluation of new natural and synthetic compounds, showing antibacterial activity along with other activities, such as antitumoral, antiviral, antiinflammatory and so on. Conversely, molecules with different biological activities have also been demonstrated to be promising antibiotics. This Special Issue, entitled "What's new: Natural and synthetic antibacterials and/or agents with multiple activities?" aims to provide an overview of the most recent and original research in this area.

Guest Editor

Prof. Dr. Maria Stefania Sinicropi

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata, Italy

Deadline for manuscript submissions

closed (31 January 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/68028

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

